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Abstract
Objective: Quantitative EEG power has not been as effective in discriminating between healthy aging 
and Alzheimer’s disease as conventional biomarkers. But EEG coherence has shown promising 
results in small samples. The overall aim was to evaluate if EEG connectivity markers can 
discriminate between Alzheimer’s disease, mild cognitive impairment, and healthy aging and to 
explore the early underlying changes in coherence. 
Methods: EEGs were included in the analysis from 135 healthy controls, 117 patients with mild 
cognitive impairment, and 117 patients with Alzheimer’s disease from six Nordic memory clinics. 
Principal component analysis was performed before multinomial regression. 
Results: We found classification accuracies of above 95% based on coherence, imaginary part of 
coherence, and the weighted phase-lag index. The most prominent changes in coherence were 
decreased alpha coherence in Alzheimer’s disease, which was correlated to the scores of the 10-word 
test in the Consortium to Establish a Registry for Alzheimer’s Disease battery. 
Conclusions: The diagnostic accuracies for EEG connectivity measures are higher than findings from 
studies investigating EEG power and conventional Alzheimer's disease biomarkers. Furthermore, 
decreased alpha coherence is one of the earliest changes in Alzheimer’s disease and associated with 
memory function. 
Significance: EEG connectivity measures may be useful supplementary diagnostic classifiers. 
Keywords:
Coherence; Imaginary part of coherence; weighted phase-lag index; EEG; Diagnostic; Alzheimer’s 
disease; Mild cognitive impairment.
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Highlights
 EEG connectivity showed diagnostic accuracies >95% between patients and healthy controls.
 Decreased alpha coherence is one of the earliest changes in Alzheimer’s disease.
 Alpha coherence is strongly associated with memory function.
Abbreviations
CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; MMSE, Mini-Mental State 
Examination 
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1. Introduction
The diagnostic criteria for the dementia disorders of different etiologies are based on findings from 
clinical assessments but most of these criteria are not very helpful in the differential diagnosis in the 
very early phases of dementia (Reiman, 2014). The use of more advanced techniques like MRI, PET 
and cerebrospinal fluid  biomarkers has proven very helpful in diagnosing Alzheimer’s disease (Korf 
et al., 2004, Mosconi et al., 2009, Visser et al., 2009, Dubois et al., 2010, Resnick et al., 2010), but 
these methods are expensive, only performed in specialized hospitals, or invasive. EEG is widely 
available, and functional connectivity measures may serve as features for a diagnostic classifier. 
Coherence, which is a method for calculating functional connectivity, refers to the temporal 
correlation between signals recorded from different brain regions. Only a few studies have shown 
that coherence alone may serve as a diagnostic marker in Alzheimer’s disease, but promising results 
with sensitivity/specificity of 87%/77% (Adler et al., 2003) and 77.8%/100% (Jelic et al., 1996) have 
been demonstrated. These two studies, however, had a small sample size and used single coherence 
values for classification (Jelic et al., 1996, Adler et al., 2003). A larger study partly used coherence 
values and found an area under the curve of the receiver operating characteristic curve of 0.90 when 
separating Alzheimer’s disease from healthy controls (Engedal et al., 2015). However, no studies 
have used coherence to separate both patients with mild cognitive impairment and Alzheimer’s 
disease from healthy controls. In addition, recent evidence has suggested that volume conduction 
through the tissue can obscure the results when applying coherence. To overcome this problem, 
studies have found that the imaginary part of coherence is insensitive to volume conduction (Grosse 
et al., 2002, Nolte et al., 2004). However, the imaginary part of coherence is still affected by the signal 
amplitudes, which may make it more sensitive to noise (Vinck et al., 2011). Recent studies have 
therefore suggested that connectivity measurements solely based on the phase relationship may be 
less sensitive to volume conduction as measured with the weighted phase-lag index (Vinck et al., 
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2011, Hardmeier et al., 2014). So far, no studies have to our knowledge tested if coherence performs 
as well as the imaginary part of coherence or the weighted phase-lag index as features for 
classification.  
Multiple studies have investigated the changes in coherence in patients with Alzheimer’s disease 
compared to healthy controls, with the most common finding being decreased alpha coherence 
(Leuchter et al., 1987, Leuchter et al., 1992, Cook and Leuchter, 1996, Locatelli et al., 1998, Wada 
et al., 1998, Jelic et al., 2000, Knott et al., 2000, Adler et al., 2003, Jeong, 2004, Sankari et al., 2011, 
Wang et al., 2014). Notwithstanding, the mentioned studies may have recruited patients with 
Alzheimer’s disease at a later stage of the disease, as indicated by the low mean for the Mini-Mental 
State Examination (MMSE) of 15.6-21.9, with one study reporting an MMSE range of 11.7-14.0 
(Wang et al., 2014). In addition, only one study included patients with mild cognitive impairment 
(Jelic et al., 2000). To understand the underlying mechanism behind coherence as a diagnostic 
marker, early coherence changes need to be further explored. 
Only few studies have investigated the association between coherence and cognitive scores (Leuchter 
et al., 1992, Dunkin et al., 1994, Knott et al., 2000, Chen et al., 2015), and no studies have looked at 
associations with cerebrospinal fluid biomarkers. This may largely be due to the multiple comparisons 
problem, if done for each connection. Another possible approach to overcoming this issue is to 
correlate the cognitive tests or cerebrospinal fluid biomarkers to total coherence (Babiloni et al., 
2010), which is the sum of all connections for each frequency band.  
As a result, the current exploratory study tests whether coherence, imaginary part of coherence or the 
weighted phase-lag index may be used as features for classification between Alzheimer’s disease, 
mild cognitive impairment, and healthy aging. We used the same protocol for the diagnostic classifier 
as previously reported (Musaeus et al., 2018a). To understand the early changes in coherence in 
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dementia due to Alzheimer’s disease, we also wanted to examine the differences in coherence 
between patients with Alzheimer’s disease, mild cognitive impairment, and healthy controls. Lastly, 
to assess the functional relevance of coherence, we tested whether total alpha coherence was 
correlated to either cognitive scores or biomarkers. 
JO
UR
NA
L P
RE
-P
RO
OF
JOURNAL PRE-PROOF
7
2. Methods and materials
2.1 Participants
The data from the current study has been used in previous publications (Engedal et al., 2015) and 
some of the subjects have also participated in another study (Musaeus et al., 2018b). The results from 
the power analysis derived from the frequency spectrum are presented elsewhere (Musaeus et al., 
2018a). The patients and the healthy controls were recruited from six Nordic memory clinics. The 
data was originally collected as part of a validation study (Engedal et al., 2015), which entailed 
ensuring that each diagnostic group comprised about 20 patients, a common requirement in validation 
studies. A minimum of 60 patients and 20 healthy controls were recruited at each site in the validation 
study. All 365 of the included study participants were consecutively recruited in most clinics during 
their first assessment using the following predefined exclusion criteria: 1) neurological disorders with 
dementia other than Alzheimer’s disease, Parkinson’s disease dementia and Lewy body dementia; 2) 
major psychiatric disorders; and 3) alcohol or drug abuse. The 146 healthy controls were recruited 
from among patients’ family members, employees at the recruiting hospitals, or through advertising. 
Due to the low number of patients with Lewy body dementia (n=10), vascular dementia (n=15), 
Parkinson’s disease dementia (n=5), frontotemporal dementia (n=4), mixed Alzheimer’s disease and 
vascular dementia (n=5), and mixed dementias (n=8), they were excluded from the analysis. Patients 
with subjective cognitive decline (n=64) were excluded in the analysis in this report. Due to either 
poor quality or lost EEGs, we had to exclude eight EEGs from healthy controls, eight from patients 
with mild cognitive impairment, and 15 from patients with Alzheimer’s disease. Lastly, three healthy 
controls were excluded due to use of either antidepressants or antipsychotics since the underlying 
condition and/or severity was unknown (see flow diagram in Fig. 1). Table 1 presents a full 
description of the included patients and healthy controls. 
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2.2 Clinical diagnostic assessment 
All patients were examined according to each memory clinic’s standards, which were similar. Clinical 
assessment comprised: 1) a history from the patient and an informant; 2) a physical examination 
focusing on neurological and cardiology status; 3) blood tests to screen for disorders that could be 
associated with cognitive impairment; 4) neuropsychological tests covering various cognitive 
domains; 5) CT or MRI of the brain to evaluate white matter changes, general atrophy, and atrophy 
of the medial temporal lobes; and 6) a lumbar puncture to examine amyloid beta-42 and total tau and 
phosphorylated tau protein in the cerebrospinal fluid, when indicated. Some patients were assessed 
with fludeoxyglucose PET or Tc-HMPAO SPECT. The neuropsychological tests for the initial 
examination differed slightly between the clinics but included both verbal and visuospatial memory 
assessments. All the patients included in this study underwent MMSE (Folstein et al., 1975), the 
Clock-Drawing Test (Shulman, 2000), and the 10-word tests of the Consortium to Establish a 
Registry for Alzheimer’s disease (CERAD) (Morris et al., 1988). A previously published paper 
contains the details of the clinical assessments (Braekhus et al., 2011). 
The clinical diagnoses were made at consensus meetings with all doctors present at each memory 
clinic, or by at least two experienced doctors, and applied the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition Text Revision and the McKhann criteria for the diagnosis of 
Alzheimer’s disease (McKhann et al., 1984). Winblad criteria were used to diagnose mild cognitive 
impairment (Winblad et al., 2004). All diagnoses were made blinded to the EEG results. After 
undergoing a cognitive test battery to rule out cognitive impairment, the healthy controls were 
interviewed and histories of previous and present disorders and drug use were recorded. Any 
individuals who had a cognitive test result below one standard deviation, according to their age, were 
excluded. 
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2.3 EEG recording
EEGs were recorded using NicoletOne EEG Systems (Natus®). The International 10-20 System of 
Electrode Placement was used for the 19 electrodes (Supplementary Figure S1), and the features were 
evaluated using the average montage. Two bipolar electro-oculography channels and one 
electrocardiogram channel were recorded to monitor artefacts. Most EEGs were recorded alternating 
between three-minute periods of eyes closed and eyes open. The participants were alerted if they 
became visibly drowsy. 
Some of the clinics participating in the study did not record segments with eyes open. As a result, the 
number of segments with eyes closed and eyes open for each group was: healthy controls (eyes closed: 
138, eyes open: 110); Alzheimer’s disease (closed: 117, open: 97); and mild cognitive impairment 
(closed: 117, open: 99).
2.4 Pre-processing EEG
The data, imported to MATLAB (Mathworks, v2016a) using the EEGLAB toolbox (Delorme and 
Makeig, 2004), was divided into eyes-closed and eyes-open segments using the events in the EEG 
during recording. Some of the EEGs did not contain eyes-open segments, and the eyes-closed 
segments were selected from the first 10 minutes of the recording to prevent inclusion of segments 
with drowsiness or sleep. The electrodes were computationally located on the scalp by means of the 
DIPFIT toolbox (Oostenveld et al., 2011). The excessive channels (like electrocardiogram and 
reference electrodes) were removed and the data was bandpass-filtered from 1-70 Hz using the 
pop_firws function in MATLAB, with a filter order of two, and the Kaiser window parameter beta 
was estimated using a maximum passband ripple of 0.001. Afterwards, the data was band-stop filtered 
from 45-55 Hz using the same settings. The data was subsequently down-sampled to 200 Hz, if the 
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sampling rate was >200 Hz. Next, the data was divided into one-second epochs and the EEGs were 
visually inspected to remove excessive noise or artefacts. Channels with excessive noise, drift, or a 
bad connection were interpolated using spherical interpolation. The EEG had to have ≤3 electrodes 
with excessive artefacts; otherwise, the EEG was excluded from the analysis. Afterwards, 
independent component analysis was performed using the extended infomax algorithm (Lee et al., 
1999), extracting up to 19 components based on the data rank. This was done for each file, and 
components containing eye blinks, eye movement, electrocardiogram artefacts, or specific line-noise 
artefacts were removed. Lastly, the EEGs were visually inspected again, and epochs with excessive 
noise or artefacts were removed. The investigator was blinded to diagnosis.
2.5 Connectivity calculations 
Coherence between two signals was calculated as the square of the cross spectrum of the electrodes 
divided by the product of the power spectra of the individual electrodes. This way of calculating 
coherence is a measure of the consistency of a phase relationship between two signals ranging from 
0 to 1. Coherence was calculated between each pair of electrodes for each of the following frequency 
bands: delta (1-3.99 Hz); theta (4-7.99 Hz); alpha (8-12.99 Hz); and beta (13-29.99 Hz), together with 
beta1 (13-17.99 Hz); beta2 (18-23.99 Hz); and beta3 (24-29.99 Hz), for eyes closed and open. The 
coherence values were calculated for each epoch separately and, afterwards, we calculated the mean 
across epochs. This was performed with the assumption that the phase relationship would be constant 
across epochs. Total coherence was calculated by averaging across all connections and was done 
separately for each frequency band and for eyes closed and open. 
The imaginary part of coherence was calculated by taking the imaginary part of the cross-spectrum 
of the electrodes divided by the square root of the product of the power spectra of the individual 
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electrodes (Nolte et al., 2004). Since we were interested in the magnitude as calculated for coherence, 
we calculated the absolute value of the imaginary result. To calculate the weighted phase-lag index, 
we applied the same approach as previously described (Vinck et al., 2011). Here, the weighted phase-
lag index was calculated across trials. Both the imaginary part of coherence and the weighted phase-
lag index was calculated for the same frequency bands as described for coherence. 
2.6 Prediction
Prediction analysis, as previously executed in the context of spectral power (Musaeus et al., 2018a), 
was performed in eyes closed and open for the three diagnoses (Alzheimer’s disease, mild cognitive 
impairment, and healthy controls). The data set, which consisted of the number of subjects using 171 
coherence values (19 electrodes) and seven frequency bins (delta, theta, alpha, beta1, beta2, beta3, 
and beta), was turned into a data matrix of number of subjects by 7*171 coherence features and 
compressed using principal component analysis, such that 99% of the data variance was kept for the 
subsequent classification analysis. For the classification, we used multinomial regression for the 
three-class classification of Alzheimer’s disease, mild cognitive impairment, and healthy controls, as 
implemented using the minFunc optimization procedure (Schmidt, 2005). We quantified the model 
performance using leave-one-out cross-validation. The classification accuracies are reported 
averaged over the number of observations (i.e., subjects) left out one at a time in the leave-one-out 
cross-validation procedure. The same procedures were performed for the imaginary part of coherence, 
and for the weighted phase-lag index. As a post-hoc analysis, we employed only alpha coherence as 
a diagnostic classifier using the same approach described above. 
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2.7 Statistics
All statistics were performed in MATLAB (vR2016a). To compare sex, we performed a chi-square 
test. For age, years of education, the MMSE, the ten-word list of the Consortium to Establish a 
Registry for Alzheimer’s Disease score and sub-scores (learning, recognition, and recall), and the 
number of 1-second epochs, we performed as a one-way ANOVA for three groups: Alzheimer’s 
disease, mild cognitive impairment, and healthy controls. The comparison was significant with a p-
value <0.05. 
When comparing the coherence values, we first performed Fisher’s Z transformation before any 
statistical test due to the non-normally distributed data. For comparing Alzheimer’s disease, mild 
cognitive impairment, and healthy controls, we performed an ANCOVA using age, sex, years of 
education, and current medication as covariates. Current medications were included as binary values 
for whether the person received antipsychotics, antidepressants, hypnotics, anti-dementia drugs, or 
painkillers. To correct for multiple comparisons, we performed Bonferroni-Holm correction for 171 
connections and seven frequency bands, which is equal to 1197 comparisons times two for eyes 
closed and open. Afterwards, we computed post-hoc t-tests without covariates on the Z-transformed 
data if the group comparison was significant after Bonferroni-Holm correction (corrected p-value 
<0.05). The post-hoc t-tests were considered significant with a p-value <0.001. The p-value was set 
at 0.001 for the post-hoc test to correct for multiple comparisons at the post-hoc level. For 
visualization of the connectivity, we used the BrainNet Viewer toolbox (Xia et al., 2013) with the 
significant t-values from the post-hoc analyses. The same approach was performed for both the 
imaginary part of coherence, and the weighted phase-lag index.
For correlation analyses, we performed a Spearman correlation between total alpha coherence when 
the participants had eyes closed and the total Consortium to Establish a Registry for Alzheimer’s 
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Disease (CERAD) score, including the sub-scores learning, recall, and recognition, and the 
Alzheimer's disease biomarkers (amyloid, total tau, and phosphorylated tau).  
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3. Results
3.1 Demographics 
Table 1 presents a description of the demographics and comparisons between groups for patients with 
Alzheimer’s disease, mild cognitive impairment, and healthy controls. The number of 1-second 
epochs between Alzheimer's disease (mean(SD) = 130.82 (53.14)), mild cognitive impairment 
(mean(SD) = 119.64 (48.23)), and healthy controls (mean(SD) = 113.93 (55.49)) was significantly 
different (p-value = 0.038, F = 3.3072, degrees of freedom = 366) looking at all the included 
participants. 
3.2 Diagnostic accuracy 
We found a classification accuracy of 95.9% (specificity = 94.07%, sensitivity for mild cognitive 
impairment = 97.44%, sensitivity for Alzheimer's disease = 96.58%) when comparing all three patient 
groups (Alzheimer’s disease, mild cognitive impairment, and healthy controls) for all coherence 
values with eyes closed (Fig. 2A). When the participants had open eyes, the accuracy was 98.0% 
(specificity = 97.20%, sensitivity for mild cognitive impairment = 96.97%, sensitivity for Alzheimer's 
disease = 100%) for all three patient groups for all coherence values (see Fig. 2D). 
For imaginary part of coherence for the eyes-closed segment, we found an accuracy of 96.7%, 
(specificity = 95.55%, sensitivity for mild cognitive impairment = 96.58%, sensitivity for Alzheimer's 
disease = 98.29%), and 98.3% (specificity = 98.13%, sensitivity for mild cognitive impairment = 
96.97%, sensitivity for Alzheimer's disease = 100%) in eyes-open condition (Figs. 2B and 2E).
For the weighted phase-lag index for the eyes-closed segment, we found an accuracy of 96.2%, 
(specificity = 97.78%, sensitivity for mild cognitive impairment = 92.31%, sensitivity for Alzheimer's 
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disease = 98.29%), and 98.3% (specificity = 100%, sensitivity for mild cognitive impairment = 
95.96%, sensitivity for Alzheimer's disease = 98.97%) in eyes-open condition (Figs. 2C and 2F).
As a post-hoc analysis, we also calculated the classification accuracy for alpha coherence between 
the three groups with eyes closed. We found an accuracy of 87.5% (specificity = 84.44%, sensitivity 
for mild cognitive impairment = 88.03%, sensitivity for Alzheimer's disease = 90.60%); see Fig. 2G.
Since the number of 1-second epochs was significantly different between the three groups, we 
examined whether there was any confounding effect (Supplementary Material, Possible confounders 
of the classifier, pp. 30-36). We found that the number of epochs was unable to predict the diagnoses. 
When similarly dividing the participants into three groups with an equal number of participants 
(below 94 epochs, between 94 to 131 epochs, and above 131 epochs), we found that the participants 
with over 131 epochs performed worse (accuracy = 81.3%) than the group with 94 to 131 epochs 
(95.1%), and the group with less than 94 epochs (97.6%). Furthermore, when only the first 94 epochs 
were included for the group with 94 to 131 epochs, we found a poor classification accuracy (42.6%). 
We also observed that systematically reducing the number of included participants reduced 
classification performance. No difference in accuracy was found when the variance preserved by the 
principal component analysis was above 90%.
3.3 Coherence – eyes closed  
For coherence, the most prominent findings were decreases for all significant electrode pairs in the 
alpha band for Alzheimer’s disease compared to healthy controls and mild cognitive impairment (Fig. 
3) For mild cognitive impairment compared to healthy controls, the decreases were less pronounced. 
Between patients with Alzheimer’s disease and healthy controls in the theta band, we found 
significant increases in coherence for almost all electrode pairs, except between Cz-Fz, Cz-T3, Cz-
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T5, Cz-T4, and T6-O2. When comparing mild cognitive impairment and healthy controls in the theta 
band, we found increases in coherence for most electrode pairs, except for decreased left temporal, 
parietal, and occipital connections, corresponding to the right hemisphere. For all the beta bands, we 
found increases and decreases between Alzheimer’s disease and healthy controls. However, patients 
with mild cognitive impairment showed a pattern of decreased coherence compared to both healthy 
controls and patients with Alzheimer’s disease, which is also the case when examining total coherence 
(Fig. 4). For significant differences in coherence in eyes closed, see Fig. 3 and, for total coherence, 
see Fig 4. Supplementary Figures S2-3 contain colourmaps, while Supplementary Tables S1-S14 and 
Tables S29-S35 present statistical results. For significant differences for eyes closed for the imaginary 
part of coherence see Supplementary Figure S11 and for the weighted phase-lag index see 
Supplementary Figure S13.
3.4 Coherence – eyes open 
The most prominent findings for eyes open were in the delta and theta bands (Figs. 5 and 6). In the 
delta band, we found an overall increase in coherence for patients with Alzheimer’s disease and a 
decrease for patients with mild cognitive impairment compared to healthy controls. In the theta band, 
we found an increase in the majority of the coherence values for patients with Alzheimer’s disease 
and patients with mild cognitive impairment compared to healthy controls. The most prominent 
connections were found between frontal electrodes and between frontal and temporal electrodes (T3-
F8, T4-F7 and F8-F3). In the beta1 and beta2 bands, we found that patients with mild cognitive 
impairment had a decreased coherence compared to patients with Alzheimer’s disease and to healthy 
controls (Figs. 5 and 6). Supplementary Figures S4-S5 contain colourmaps, while Supplementary 
Tables S15-S28 and Tables S36-S42 present statistical results. For significant differences for eyes 
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open for the imaginary part of coherence see Supplementary Figure S12 and for the weighted phase-
lag index see Supplementary Figure S14.
3.5 Association with cognitive scores and Alzheimer's disease biomarkers
We found that total alpha coherence was significantly correlated to the CERAD score (p-value 
<0.000, rho = 0.4438), including the sub-scores for learning (p-value <0.000, rho = 0.4269), delayed 
recall (p-value <0.000, rho = 0.4304), and recognition (p-value <0.000, rho = 0.3109). In addition, 
we found that total alpha coherence was significantly correlated with the MMSE score (p-value 
<0.000, rho = 0.3991). No significant correlations were found between Alzheimer's disease 
biomarkers and total alpha coherence. Supplementary Figure S4 shows the scatterplots for the 
significant correlations. 
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4. Discussion
In the present study, we found accuracies above 95% when separating Alzheimer’s disease, mild 
cognitive impairment, and healthy controls using either EEG coherence, the imaginary part of 
coherence, or the weighted phase-lag index. Furthermore, when only using the alpha band coherence, 
we find an accuracy of 87.5%. The most prominent early coherence changes were decreased alpha in 
Alzheimer’s disease and, to a lesser extent, for patients with mild cognitive impairment compared to 
healthy older controls in eyes closed condition. We found that total alpha coherence was positively 
correlated with the CERAD 10-word list scores. Furthermore, we found an overall decreased beta 
coherence in patients with mild cognitive impairment compared to both Alzheimer’s disease and 
healthy controls. 
Two previous studies examining EEG coherence to discriminate between Alzheimer’s disease and 
healthy aging showed a sensitivity/specificity of 87%/77% (Adler et al., 2003) and 77.8%/100% (Jelic 
et al., 1996), but they had a low number of participants, used single coherence values for the 
classification, and did not include mild cognitive impairment. One study had 31 participants with 
Alzheimer’s disease and 17 who were cognitively unimpaired and depressed (Adler et al., 2003), 
while the other had less than 20 participants in each group (Jelic et al., 1996). In the current study, 
we used a predefined protocol (Musaeus et al., 2018a) and performed principal component analysis, 
which included all frequency bands into one prediction analysis and the study was conducted in a 
large population. Compared to conventional EEG measurements, we previously found in the same 
population that EEG power was unable to separate Alzheimer’s disease, mild cognitive impairment, 
and healthy controls (accuracies between 48.0%-53.5%) (Musaeus et al., 2018a). Furthermore, other 
studies using EEG power have found promising results (Claus et al., 1999, Lehmann et al., 2007, 
Snaedal et al., 2012) but had low sample size (Claus et al., 1999) or were not able to replicate the 
findings (Ommundsen et al., 2011). However, more advanced EEG techniques, such as feature 
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selection algorithms (Trambaiolli et al., 2017), entropy (Abasolo et al., 2005), and amplitude 
modulation (Fraga et al., 2013), have shown promising results but with low sample sizes. In addition, 
the accuracies above 95% are higher than conventional Alzheimer's disease biomarkers, including 
fludeoxyglucose PET, cerebrospinal fluid biomarkers, or MRI, which has been shown to be >80% 
(Frisoni et al., 2013). Consequently, we suggest that quantitative EEG coherence can serve as a 
supplemental classifier to differentiate between Alzheimer’s disease, mild cognitive impairment, and 
healthy controls. In further support of this, we found that using imaginary part of coherence, and the 
weighted phase-lag index, which both should be less affected by volume conduction, had accuracies 
close to coherence. When including only alpha coherence, which constituted the most pronounced 
changes, we found an accuracy of 85.1%. This indicates that including other frequency bands may 
increase the diagnostic accuracy. These are very promising findings, but future studies are needed to 
validate them, and other groups of neurodegenerative diseases should possibly be added to the 
diagnostic classifier. Furthermore, to our knowledge, no studies have used coherence with eyes open 
to predict diagnosis of dementia due to Alzheimer’s disease, which is useful since patients with closed 
eyes may get drowsy or fall asleep during the EEG recording. Furthermore, this is the first study using 
the imaginary part of coherence, and the weighted phase-lag index as a classifier of disease in patients 
with Alzheimer’s disease. 
We also studied any potential confounding effect of the number of trials included (see Supplementary 
Material, Possible confounders of the classifier, pp. 30-36). We found that the number of epochs was 
unable to predict the diagnoses. However, we found that the classifier performed worse in the group 
that had more than 131 epochs compared to the groups with lengths less than 131 epochs. This may 
indicate that either the patients with larger datasets, and therefore the ability to comply with the 
protocol, were in a milder stage of the disease or even misdiagnosed, or that we included sleep during 
the preprocessing. Furthermore, we were unable to reproduce the diagnostic accuracy of 95.1% in the 
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group with 94 to 131 epochs when only the first 94 epochs were included, with an accuracy of only 
42.6% achieved. This suggests that reducing the signal-to-noise ratio (by reducing the number of 
epochs) has a profound effect on the classification accuracy. We investigated the performance when 
reducing the amount of variance preserved to 70%, 80%, 90%, 95%, 97.5%, and 99% and observed 
that classification performance declined when preserving less than 95% of the variance, but the 
performance saturated when 95% or more of the variance was preserved. This indicates that 
discriminatory signals in the low variance components do not have any considerable effect on 
classification accuracy. By systematically reducing the number of participants, we observed that the 
classification performance was reduced but, even when only including 100 subjects, we achieved a 
high classification performance of well above 80% when preserving 95% or more of the variance in 
the principal component analysis. Future studies should thus record larger EEG datasets and 
systematically test whether the effect of epochs on classification performance is driven by changes in 
the signal-to-noise ratio.
The most prominent coherence change in Alzheimer’s disease was a large decrease in alpha 
coherence compared to both mild cognitive impairment and healthy controls with eyes closed at the 
time of diagnosis (Figs. 3 and 4), which is in line with previous research (Leuchter et al., 1987, 
Leuchter et al., 1992, Cook et al., 1996, Locatelli et al., 1998, Wada et al., 1998, Jelic et al., 2000, 
Knott et al., 2000, Adler et al., 2003, Jeong, 2004, Sankari et al., 2011, Wang et al., 2014) (Fig. 3). 
The underlying mechanism for decreased alpha coherence in Alzheimer’s disease is still controversial 
but has been attributed to a decrease in cholinergic connectivity (Locatelli et al., 1998, Adler et al., 
2003), which is explained by decreased alpha coherence after administration of anticholinergic drugs 
like scopolamine (Sloan et al., 1992, Bajo et al., 2015). In further support of this, decreased alpha 
band coherence has also been associated with the ApoE4 genetic risk factor (Jelic et al., 1997), and 
studies have found that cholinesterase inhibitors lead to greater cognitive improvement in patients 
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with the ApoE4 genetic risk factor (Bizzarro et al., 2005, Petersen et al., 2005, Choi et al., 2008, 
Patterson et al., 2011), which may indicate a more pronounced decrease in cholinergic function. In 
patients with mild cognitive impairment, we also showed a decrease in alpha coherence, which is in 
line with previous studies (Jelic et al., 1996, Moretti et al., 2008, Bian et al., 2014), but it was not as 
pronounced as in Alzheimer’s disease. We hypothesize that the underlying degenerative processes of 
the cholinergic system may have led to the decreased alpha coherence, which is not as pronounced in 
patients with mild cognitive impairment and supports the idea of coherence as a classifier of disease. 
However, studies investigating the EEG effect of cholinesterase inhibitors in patients with 
Alzheimer’s disease are needed. Furthermore, we found positive significant correlations between 
cognitive scores and total alpha coherence, and especially the total CERAD score (p-value <0.000, 
rho = 0.4438) and delayed recall (p-value <0.000, rho = 0.4304). A recent study showing that 
longitudinal changes in cognition were correlated to C3-C4 and P3-P4 alpha coherence support this 
finding (Chen et al., 2015). These results combined point to decreased alpha coherence as a hallmark 
of early Alzheimer’s disease. Unfortunately, the PET data was not available for the current study.
Previous studies found very heterogeneous results in the eyes closed condition in the delta and theta 
bands, with decreases and increases in coherence (Leuchter et al., 1987, Locatelli et al., 1998, Adler 
et al., 2003, Brunovsky et al., 2003, Sankari et al., 2011, Wang et al., 2014), with most studies finding 
a general decrease in coherence. In the delta band, studies found no differences using global scores 
(Besthorn et al., 1994, Jelles et al., 2008), specific increases (Locatelli et al., 1998) or decreases 
(Sankari et al., 2011) between electrode pairs in patients with Alzheimer’s disease compared with 
healthy controls, which can explain the mixed results in the current study (Fig. 3). In the theta band, 
some studies found a decrease (Besthorn et al., 1994, Sankari et al., 2011), but this may be due to a 
small sample size. We found an overall increase in theta coherence (Fig. 3), which can partially be 
explained as an overall increase in spectral theta power, as previously reported with the same dataset 
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(Musaeus et al., 2018a). We also found decreased coherence in the beta bands in mild cognitive 
impairment compared to both Alzheimer’s disease and healthy controls (Fig. 3, and Fig. 4), which 
has not previously been reported and needs to be explored further. We also investigated the eyes open 
condition, which, to our knowledge, has not been investigated previously, and found that the most 
pronounced changes were in the theta and delta bands (Fig 5). The increased theta band coherence in 
patients with Alzheimer’s disease and patients with mild cognitive impairment compared to healthy 
controls, which we also found in the eyes closed condition, may be related to our previous finding of 
increase spectral theta power (Musaeus et al., 2018a). The current study has some limitations; for 
example, the lack of follow-up data in the mild cognitive impairment group prevented us from 
investigating mild cognitive impairment with Alzheimer’s disease pathology. In addition, we decided 
not to include the gamma frequency band in the analysis since the EEGs in the current study were 
recorded in a clinical setting, which included high-frequency noise that especially affected the gamma 
band. Furthermore, the coherence measure may be subject to common feeding effects (Dauwels et 
al., 2010, Blinowska and Kaminski, 2013), possibly leading to spurious connections, which is why 
any conclusions regarding specific connections have been avoided. Demographically, we found that 
the healthy controls were younger than the Alzheimer’s disease and mild cognitive impairment 
groups, and a proportion of Alzheimer’s disease and mild cognitive impairment patients were being 
treated with medications that may have affected the EEG. Furthermore, the healthy control group had 
a higher level of education than either clinical group, which may also have played a role in memory 
impairment. However, we tried to correct for these confounders by including age, medication, and 
education as covariates when performing ANCOVA. The current study, which is the largest 
prospective multi-center study to date with consecutively recruited patients at an early stage of 
Alzheimer’s disease applying coherence, imaginary part of coherence, and weighted phase-lag index, 
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found accuracies >95% when predicting Alzheimer’s disease, mild cognitive impairmentand healthy 
aging, which is very promising.  
5. Conclusions 
The current study found that coherence, the imaginary part of coherence, and the weighted phase-lag 
index are very promising classifiers (accuracies >95 %) for Alzheimer’s disease, mild cognitive 
impairment, and healthy aging, because the accuracies are higher than for both quantitative EEG 
power and conventional biomarkers like MRI, fludeoxyglucose PET, and cerebrospinal fluid 
biomarkers. Furthermore, in patients with Alzheimer’s disease, we found the largest decrease in alpha 
coherence and, to a lesser extent, for patients with mild cognitive impairment at the time of diagnosis, 
which was positively correlated with memory function. We hypothesize that the decreased alpha 
coherence is the EEG coherence hallmark of early Alzheimer’s disease. These findings suggest that 
EEG coherence, imaginary part of coherence, and the weighted phase-lag index may be used as 
supplementary diagnostic tools. However, a validation of the classifier in a separate cohort is needed. 
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Table 1. Characteristics of study participants.
HC = healthy controls, AD = Alzheimer’s disease, MCI = mild cognitive impairment, SD = standard deviation, MMSE = Mini-Mental 
State Examination. P-values show the differences when comparing patients with Alzheimer’s disease, mild cognitive controls, and 
healthy controls. A p-value was considered significant when p-value <0.05. 
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Fig 1. Flow diagram of the number of included participants in the current study and the excluded participants after 
preprocessing.
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Fig 2. Confusion matrices displaying results from the prediction analyses for A) coherence with eyes closed, B) 
imaginary part of coherence with eyes closed,  C) weighted phase-lag index with eyes closed, D) coherence with eyes 
open, E) imaginary part of coherence with eyes open, F) weighted phase-lag index with eyes closed and G) coherence in 
the alpha band for eyes closed. HC = healthy controls, AD = Alzheimer’s disease, MCI = mild cognitive impairment.
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Fig 3. Difference in coherence between groups (Alzheimer’s disease vs. healthy controls; mild cognitive impairment vs. 
healthy controls; and Alzheimer’s disease vs. mild cognitive impairment) for all seven frequency bands (A-G) with eyes 
closed. The difference is illustrated if the post-hoc test was significant (<0.001), and t-values were used to illustrate the 
differences. Red indicates increased and blue decreased coherence in the first group listed (i.e., decreased alpha coherence 
between Alzheimer’s disease and healthy controls can be found in row C column one, AD vs. HC). HC = healthy controls, 
AD = Alzheimer’s disease, MCI = mild cognitive impairment.
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Fig 4. Total coherence in each frequency band for eyes closed. The comparison is considered significant if the ANCOVA 
was significant and the post-hoc t-test was significant (p-value <0.05). *1 = significant differences between all groups; 
*2 = significant difference between MCI and both HC and AD. HC = healthy controls, AD = Alzheimer’s disease, MCI 
= mild cognitive impairment. 
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Fig 5. Difference in coherence between groups (Alzheimer’s disease vs. healthy controls; mild cognitive impairment vs. 
healthy controls; and Alzheimer’s disease vs. mild cognitive impairment) for the delta, theta, alpha, and beta bands (A-
D) with eyes open. The difference is illustrated if the post-hoc test was significant (<0.001), and t-values were used to 
illustrate the differences. Red indicates increased and blue decreased coherence in the first group listed. HC = healthy 
controls, AD = Alzheimer’s disease, MCI = mild cognitive impairment.
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Fig 6. Total coherence in each frequency band for eyes open. The comparison is considered significant if the ANCOVA 
was significant and the post-hoc t-test was significant (p-value <0.05). *1 = significant differences between all groups; 
*2 = significant difference between MCI and both HC and AD; *3 = significant difference between HC and both MCI 
and AD; *4 = significant difference between MCI and HC. HC = healthy controls; AD = Alzheimer’s disease; MCI = 
mild cognitive impairment. 
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 HC MCI AD p-value
 (n=135) (n=117) (n = 117) AD vs MCI vs HC
Mean age (SD), years
66.44 
(7.64) 70.15 (8.13) 75.49 (7.65) <0.000
Sex (female), % 60.7 53 60.7 0.377
Education, years (SD)
13.89 
(3.61) 11.57 (3.92) 10.07 (3.39) <0.000
Antipsychotics 0 1 4  
Antidepressants 0 25 18  
Tranquilizers/hypnotics 3 12 6  
Anti-dementia drugs 0 2 18  
Painkillers 4 6 4  
Lumbar punctures performed  38 32  
Amyloid beta 42, mean (SD)  
876.16 
(354.92)
516.34 
(114.52) <0.000
Total tau, mean (SD)  
420.98 
(230.51)
532.31 
(273.85) 0.069
Phosphorylated tau, mean (SD)  63.16 (26.72)
106.33 
(114.52) 0.027
MMSE, mean (SD)
28.91 
(1.34) 27.11 (2.16) 23.52 (3.79) <0.000
Word list memory, mean (SD)
20.49 
(3.99) 15.25 (4.29) 11.06 (3.83) <0.000
Word list recall, mean (SD) 7.39 (1.69) 3.66 (2.34) 1.52 (1.64) <0.000
Word list recognition, mean 
(SD)
19.47 
(1.44) 17.92 (2.01) 15.84 (2.62) <0.000
CERAD Word List, mean (SD)
47.46 
(5.55) 36.84 (7.39) 28.47 (6.44) <0.000
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